Indee Gold Mine

Indee Labs Announces Exclusive Distribution Deal for With Sunko Instruments in China

Retrieved on: 
Thursday, May 25, 2023
Biotechnology, Electroporation, Partnership, Labs, Marketing, Fine chemical, Indee Gold Mine

BERKELEY, Calif., May 25, 2023 /PRNewswire/ -- Indee Labs is a biotechnology company developing the Hydropore™ for non-viral intracellular delivery. Sunko Instruments is a professional distributor of scientific and laboratory instruments in China.

Key Points: 
  • Indee Labs announces an exclusive marketing and distribution deal with Sunko Instruments in China for Hydropore Research Use Only.
  • Indee Labs announces an exclusive marketing and distribution deal with Sunko Instruments in China for Hydropore.
  • As part of the partnership, Indee Lab provides Sunko Instruments with exclusive marketing and distribution rights in China for Hydropore RUO.
  • We are excited to expand Hydropore's reach to China with an exclusive marketing and distribution agreement with Sunko Instruments."

Indee Labs Adopts Scispot to Operate as a Digital Biotech Company

Retrieved on: 
Thursday, May 11, 2023
Data management, Partnership, Medical University of South Carolina, Workflow, ELN, Stanford University, CFR, Medical school, Research, SOC, Electronic lab notebook, Automation, Immunotherapy, Bangladesh Technical Education Board, Social capital, Founders Fund, Indee Gold Mine, SOC 2, UCSF, Y Combinator, Laboratory information management system, Title 21 CFR Part 11, LIMS, Digital platform, HIPAA, D, Fine chemical

KITCHENER, ON, May 11, 2023 /PRNewswire-PRWeb/ -- Scispot, the creator of the best tech stack for modern biotech, announces its partnership with Indee Labs, the developer of Hydropore™ for non-viral intracellular delivery. This collaboration aims to empower Indee Labs to digitalize and centralize their research and development processes, leveraging Scispot's no-code operating platform for enhanced efficiency, compliance, and automation, enabling them to operate as a true Digital Biotech company.

Key Points: 
  • Transforming Biotech R&D: Indee Labs Leverages Scispot's Digital Platform for Enhanced Efficiency, Compliance and Automation
    KITCHENER, ON, May 11, 2023 /PRNewswire-PRWeb/ -- Scispot , the creator of the best tech stack for modern biotech, announces its partnership with Indee Labs, the developer of Hydropore™ for non-viral intracellular delivery.
  • This collaboration aims to empower Indee Labs to digitalize and centralize their research and development processes, leveraging Scispot's no-code operating platform for enhanced efficiency, compliance, and automation, enabling them to operate as a true Digital Biotech company.
  • With Scispot, Indee Labs and other Scispot customers can efficiently meet stringent compliance requirements, such as HIPAA, SOC 2, and CFR Part 11, ensuring a secure and compliant research environment.
  • "We're thrilled to partner with Indee Labs and support their innovative work in immunotherapy," said Guru Singh, founder & CEO of Scispot.

Indee Labs Announces Strategic Investment from BroadOak BioTools Venture Fund

Retrieved on: 
Wednesday, April 12, 2023
Broad, Operating partner, West Pharmaceutical Services, DNA, Partnership, Innova Capital Partners, Cell therapy, Research, Dicarboxylic acid, Medicine, Cell, Labs, Fine chemical, Pharmaceutical industry, Vaccine, Indee Gold Mine

BERKELEY, Calif., April 12, 2023 /PRNewswire/ -- Indee Labs, the developer of Hydropore™ for non-viral intracellular delivery, is partnering with BroadOak Capital Partners, a leading direct investment and advisory firm focused on life science research tools, pharmaceutical services and diagnostics, and DeciBio Consulting, a boutique life science strategy consulting firm to complete the development and launch of Hydropore RUO.

Key Points: 
  • Indee Labs to complete the development and launch of Hydropore RUO and Cell Therapy along with a direct DNA knock-in kit, enabled by BroadOak's strategic investment and domain expertise.
  • Indee Labs to launch Hydropore RUO and Cell Therapy, enabled by BroadOak's strategic investment and domain expertise.
  • "We are excited that our first investment of the BroadOak BioTools Venture Fund will support a leading technology that will unlock the potential of this transformative modality."
  • BroadOak's BioTools Venture Fund combines BroadOak's and DeciBio's deep technical expertise, sector-specific focus, and extensive network to support companies enabling the precision medicine and gene-therapy revolution.

Indee Labs Partners with GenScript to Develop Direct DNA Knock-in Kit for Large Transgene Inserts

Retrieved on: 
Thursday, February 16, 2023
DNA, AAV, Messenger, Electroporation, Indee Gold Mine, RNP, MRNA vaccine, RUO, CRISPR, Cell, HDR, GenScript Biotech, Transgene, Genome, Uniloc USA, Inc. v. Microsoft Corp., Doctor of Philosophy, Vaccine

BERKELEY, Calif., Feb. 16, 2023 /PRNewswire/ -- Indee Labs, the developer of Hydropore™ for non-viral intracellular delivery, is partnering with GenScript USA Inc., the world's leading provider of life-science research tools and services, to deliver GenScript's non-viral DNA payloads into cells at greater efficiency, and to enable the integration of longer DNA inserts than those allowed by traditional viral methods.

Key Points: 
  • As part of the collaboration, GenScript is providing a variety of single-strand and double-strand (ssDNA and dsDNA) constructs for direct DNA inserts, while the team at Indee Labs is optimizing the Hydropore protocol and evaluating functional differences between T cells processed with Hydropore and electroporation.
  • Looking ahead, the companies will work on co-marketing a complete non-viral solution to the gene and cell therapy community.
  • One powerful application of CRISPR/Cas genome editing technology involves the precise insertion of DNA sequences via the homology-directed repair (HDR) pathway.
  • We are now excited to focus on enabling direct DNA inserts using GenScript's DNA capabilities," said Ryan Pawell, CEO of Indee Labs.

Indee Labs Partners With Monomer Bio to Automate Engineered Immune Cell Culture

Retrieved on: 
Thursday, December 1, 2022
Software, Social capital, Labs, Multimedia, Machine learning, Partnership, Medical University of South Carolina, Biotechnology, UCSF, Medical school, Founders Fund, Y Combinator, GMP, Buffer, Electroporation, Stanford University, Automation, Research, Algorithm, Vaccine, Fine chemical, Indee Gold Mine, Science

BERKELEY, Calif. and PACIFICA, Calif., Dec. 1, 2022 /PRNewswire/ -- Indee Labs is a biotechnology company developing the Hydropore™ for non-viral intracellular delivery. Monomer Bio enables cell culture at scale by providing intelligent automation software that allows labs to build fully automated workcells using readily available equipment.

Key Points: 
  • Indee Labs partners with Monomer Bio to automate Hydroporeworkflows for engineered T cells and similar immune cell types.
  • Monomer Bio enables cell culture at scale by providing intelligent automation software that allows labs to build fully automated workcells using readily available equipment.
  • Indee Labs partners with Monomer Bio to automate cell culture workflows for engineered immune cells.
  • Monomer Bio is a venture backed team of experienced operators and works with some of the most cutting-edge biotech companies like Indee Labs, Science, E11, and Modulo Bio.

Indee Labs Issued United States and International Patents for Intracellular Delivery System

Retrieved on: 
Thursday, December 12, 2019
Technology, Venture capital, Genetics, Professional services, Biotechnology, Hardware, Health, Other Science, Science, Biotechnology, Nanotechnology, Microfluidics, Vortex, Patent, Indee Gold Mine, Articles, Technology, Nature

Indee Labs, a biotechnology company developing a scalable, non-viral intracellular delivery system based on microfluidic vortex shedding (VS), today announced the United States Patent Office has issued U.S. Patent No.

Key Points: 
  • Indee Labs, a biotechnology company developing a scalable, non-viral intracellular delivery system based on microfluidic vortex shedding (VS), today announced the United States Patent Office has issued U.S. Patent No.
  • The Indee Labs group of companies is assigned and has exclusive rights to all patents, patent applications and proprietary information.
  • We are excited to announce exclusive rights to our core technology, intracellular delivery with microfluidic vortex shedding, in multiple major jurisdictions including the United States, stated Ryan Pawell, CEO of Indee Labs.
  • Indee Labs is a biotechnology company developing scalable hardware for intracellular delivery using microfluidic vortex shedding (VS).

Indee Labs Announces Formation of Strategic Advisory Board

Retrieved on: 
Wednesday, May 22, 2019
Stem cells, Venture capital, Health, Biotechnology, Clinical trials, Genetics, Medical devices, Oncology, Pharmaceutical, Professional services, Indee Gold Mine, Pilbara

Inc. (Indee Labs America) and Indee.

Key Points: 
  • Inc. (Indee Labs America) and Indee.
  • Ltd. (Indee Labs Australia) known collectively as Indee Labs announced, today, the formation of a Strategic Advisory Board (SAB).
  • The formation of the SAB will strengthen the existing scientific leadership of Indee Labs and will add the clinical expertise of its newest advisor, Dr. Kenneth Micklethwaite.
  • The Indee Labs team has already demonstrated revolutionary improvements over existing intracellular delivery methods including scalability, high yield (i.e.